PhageNova Bio Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

PhageNova Bio General Information

Description

Operator of a gene-therapy-based biotechnology platform intended to use bacteriophages to treat cancer cells. The company's platform combines the targeting capability of bacteriophages and the sustained gene expression of adeno-associated viruses, enabling physicians to target specific cancer cells without harming healthy cells.

Contact Information

Website
www.phagenovabio.com
Formerly Known As
AAVP Biosystems
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Thomas O. Daniel Research Incubator and Collaboration Center
  • 556 Morris Avenue, S7-F3
  • Summit, NJ 07901
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Thomas O. Daniel Research Incubator and Collaboration Center
  • 556 Morris Avenue, S7-F3
  • Summit, NJ 07901
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PhageNova Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Out of Business 18-Sep-2026 Completed Out of Business
7. Grant 01-Jun-2022 Completed Clinical Trials - Phase 3
6. Secondary Transaction - Private 01-Oct-2021 Completed Clinical Trials - Phase 3
5. Later Stage VC 27-Mar-2020 Completed Clinical Trials - Phase 3
4. Early Stage VC (Series A) 01-Jan-2016 Completed Clinical Trials - Phase 3
3. Equity Crowdfunding Completed Clinical Trials - Phase 3
2. Early Stage VC 05-Jun-2013 $600K Completed Clinical Trials - Phase 3
1. Angel (individual) $600K $600K Completed Startup
To view PhageNova Bio’s complete valuation and funding history, request access »

PhageNova Bio Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

PhageNova Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4175674-A2 Enhancing immune responses through targeted antigen expression Pending 06-Jul-2020
EP-4175674-A4 Enhancing immune responses through targeted antigen expression Pending 06-Jul-2020
US-20230241203-A1 Enhancing immune responses through targeted antigen expression Pending 06-Jul-2020
WO-2022010813-A2 Enhancing immune responses through targeted antigen expression Inactive 06-Jul-2020
WO-2022010813-A3 Enhancing immune responses through targeted antigen expression Inactive 06-Jul-2020 A61P31/14
To view PhageNova Bio’s complete patent history, request access »

Ready to get started?

Request a free trial

PhageNova Bio FAQs

  • When was PhageNova Bio founded?

    PhageNova Bio was founded in 2012.

  • Where is PhageNova Bio headquartered?

    PhageNova Bio is headquartered in Summit, NJ.

  • What industry is PhageNova Bio in?

    PhageNova Bio’s primary industry is Drug Discovery.

  • Is PhageNova Bio a private or public company?

    PhageNova Bio is a Private company.

  • What is PhageNova Bio’s current revenue?

    The current revenue for PhageNova Bio is .

  • How much funding has PhageNova Bio raised over time?

    PhageNova Bio has raised $8.6M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process